• Something wrong with this record ?

Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients

I. Kolarova, B. Melichar, J. Vanasek, A. Ryska, K. Horackova, J. Petera, M. Vosmik, I. Sirak, M. Dolezel

. 2021 ; 165 (1) : 19-25. [pub] 20210204

Language English Country Czech Republic

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21028017

Tumor biology plays a crucial role in the systemic treatment, specifically in HER2-positive tumors. Distinct biological behavior of breast cancer subtypes is associated with different rates of locoregional recurrence (LRR). HER2- positive breast cancer patients treated with surgery in combination with radiation, without trastuzumab have poor outcome, including high LRR. The efficacy of radiotherapy in HER-2-positive breast cancer appears to be associated with the expression of estrogen receptors. In patients with HER-2-positive breast cancer, studies conducted before the introduction of trastuzumab indicated higher benefit of adjuvant radiation in patients with hormone receptor-positive tumors compared to patients with tumors not expressing hormone receptors. The introduction of agents targeting HER-2 has transformed the management of these patients, resulting in improved outcomes. The data of clinical studies show that the administration of trastuzumab as part of a multimodality approach (with radiation based on standard guidelines) results in improved outcomes, including lower locoregional recurrence. The risk of cardiac toxicity associated with radiation to the heart and administration of potential cardiotoxic trastuzumab is not clear. In patients treated concomitantly with regional lymph node irradiation and anti-HER-2 agents after prior anthracycline-based chemotherapy minimizing the dose to the myocardium, e.g. respiratory gating or proton beam radiotherapy, have been suggested.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21028017
003      
CZ-PrNML
005      
20211129142956.0
007      
ta
008      
211105s2021 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2021.007 $2 doi
035    __
$a (PubMed)33542544
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Kolářová, Iveta $7 xx0110482 $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Czech Republic $u Faculty of Health Studies, Pardubice University, Pardubice, Czech Republic
245    10
$a Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients / $c I. Kolarova, B. Melichar, J. Vanasek, A. Ryska, K. Horackova, J. Petera, M. Vosmik, I. Sirak, M. Dolezel
504    __
$a Literatura
520    9_
$a Tumor biology plays a crucial role in the systemic treatment, specifically in HER2-positive tumors. Distinct biological behavior of breast cancer subtypes is associated with different rates of locoregional recurrence (LRR). HER2- positive breast cancer patients treated with surgery in combination with radiation, without trastuzumab have poor outcome, including high LRR. The efficacy of radiotherapy in HER-2-positive breast cancer appears to be associated with the expression of estrogen receptors. In patients with HER-2-positive breast cancer, studies conducted before the introduction of trastuzumab indicated higher benefit of adjuvant radiation in patients with hormone receptor-positive tumors compared to patients with tumors not expressing hormone receptors. The introduction of agents targeting HER-2 has transformed the management of these patients, resulting in improved outcomes. The data of clinical studies show that the administration of trastuzumab as part of a multimodality approach (with radiation based on standard guidelines) results in improved outcomes, including lower locoregional recurrence. The risk of cardiac toxicity associated with radiation to the heart and administration of potential cardiotoxic trastuzumab is not clear. In patients treated concomitantly with regional lymph node irradiation and anti-HER-2 agents after prior anthracycline-based chemotherapy minimizing the dose to the myocardium, e.g. respiratory gating or proton beam radiotherapy, have been suggested.
650    _2
$a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
650    _2
$a nádory prsu $x farmakoterapie $x metabolismus $x radioterapie $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a receptor erbB-2 $x biosyntéza $7 D018719
650    _2
$a trastuzumab $x terapeutické užití $7 D000068878
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Melichar, Bohuslav, $d 1965- $7 skuk0000853 $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Czech Republic $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic
700    1_
$a Vaňásek, Jaroslav, $d 1952- $7 nlk19990073982 $u Faculty of Health Studies, Pardubice University, Pardubice, Czech Republic $u Oncology Centre, Multiscan, Pardubice, Czech Republic
700    1_
$a Ryška, Aleš, $d 1970- $7 nlk20020124969 $u The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital Hradec Kralove, Czech Republic
700    1_
$a Horáčková, Kateřina $7 xx0146814 $u Faculty of Health Studies, Pardubice University, Pardubice, Czech Republic
700    1_
$a Petera, Jiří, $d 1959- $7 xx0000229 $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Czech Republic $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic
700    1_
$a Vošmik, Milan, $d 1972- $7 xx0135408 $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Czech Republic $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic
700    1_
$a Sirák, Igor $7 xx0135409 $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Czech Republic $u Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic
700    1_
$a Doležel, Martin $7 xx0075943 $u Department of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic $u Department of Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 1 (2021), s. 19-25
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33542544 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20211105 $b ABA008
991    __
$a 20211116154857 $b ABA008
999    __
$a ok $b bmc $g 1728679 $s 1148562
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 165 $c 1 $d 19-25 $e 20210204 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20211105

Find record

Citation metrics

Archiving options